Ibrahim T. Aldoss, M.D.
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Hematology & Hematopoietic Cell Transplantation
- Immunotherapy
- Allogenic Stem Cell Transplant
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Ibrahim T. Aldoss, M.D., is a hematologist-oncologist and board-certified in internal medicine, medical oncology and hematology. His clinical expertise is in acute lymphoblastic leukemia and acute myeloid leukemia.
Dr. Aldoss is also an associate professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, and an active Gehr Family Center Leukemia member. He is the co-director of the Hematology Tissue Bank at City of Hope and the co-director of the Leukemia Registry. His primary research focus is on optimizing treatment outcomes of younger adults with acute lymphocytic leukemia (ALL), improving immunotherapies in ALL, understanding methods of resistance, identifying alternate promising targets in ALL beyond CD19, improving transplant outcomes in ALL and understanding the genetics and the pathogenies of ALL. He is also the principal investigator on several novel therapies in acute leukemias.
Dr. Aldoss earned his medical degree from Jordan University of Science and Technology in Irbid, Jordan. He completed his residency in internal medicine at Creighton University in Omaha, Nebraska, before joining Keck School of Medicine of USC to pursue a fellowship in hematology/oncology. While at USC, Dr. Aldoss was chosen to be chief of hematology fellows and served as a clinical instructor. He joined City of Hope as a bone marrow transplantation fellow in 2014. He has published over 100 articles in the peer-reviewed literature, and he has presented his research work at many international meetings.
Location
Duarte Cancer Center
Duarte, CA 91010
Orange County Lennar Foundation Cancer Center
Irvine, CA 92618
Education & Experience
2006, M.D., Jordan University of Science and Technology, Irbid, Jordan
2010-2013, University of Southern California, Los Angeles, CA
2007-2010, Internal Medicine at Creighton University, Omaha, NE
2020-present, Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2014-2020, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2014, BMT Fellow, City of Hope, Duarte, CA
2013, Clinical Instructor, Hematology and Bone Marrow Transplantation Department, University of Southern California, Los Angeles, CA
2012-2013, Chief of Hematology Fellows, University of Southern California, Los Angeles, CA
Publications
Pourhassan H, Agrawal V, Pullarkat V, Aldoss I. Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment. Front Oncol. 2023 Aug 17;13:1237031. doi: 10.3389/fonc.2023.1237031. PMID: 37664035; PMCID: PMC10470626.
Aribi A, Salhotra A, Afkhami M, Munteanu A, Ali H, Aldoss I, Otoukesh S, Al Malki MM, Sandhu KS, Koller P, Arslan S, Stewart F, Artz A, Curtin P, Ball B, O'Hearn J, Spielberger R, Smith E, Budde E, Nakamura R, Stein A, Forman S, Marcucci G, Becker PS, Pullarkat V. WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens. Leuk Lymphoma. 2023 Aug 3:1-11. doi: 10.1080/10428194.2023.2241096. Epub ahead of print. PMID: 37533373.
Locatelli F, Shah B, Thomas T, Velasco K, Adedokun B, Aldoss I, Gore L, Hoelzer D, Bassan R, Park JH, Boissel N, Kantarjian H. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma. 2023 Aug 1:1-19. doi: 10.1080/10428194.2023.2232496. Epub ahead of print. PMID: 37526512.
Aldoss I, Tizro P, Bedi D, Mangan JK, Clark MC, Spencer D, Song JY, Cherian S, Pillai R, Kim Y, Mahajan N, Gendzekhadze K, James M, Jacobs K, Davidson-Moncada J, Forman SJ, Wang HY, Afkhami M. Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia. Haematologica. 2023 Jul 20. doi: 10.3324/haematol.2023.283566. Epub ahead of print. PMID: 37470155.
Aldoss I, Khaled SK, Wang Y, Wang X, Palmer J, Clark MC, Wagner JR, Paul J, Vyas V, Brown CE, Forman SJ. Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2023 Jul 12;13(1):107. doi: 10.1038/s41408-023-00881-z. PMID: 37438346; PMCID: PMC10338536.
Agrawal V, Aldoss I. Searching for the optimal sequence of dual-targeted CAR T cells in relapsed/refractory acute lymphoblastic leukemia. Chin Clin Oncol. 2023 Aug;12(4):33. doi: 10.21037/cco-23-31. Epub 2023 Jun 28. PMID: 37431234.
Murphy L, Aldoss I. More opportunities to advance paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia. Lancet Haematol. 2023 Jul;10(7):e479-e481. doi: 10.1016/S2352-3026(23)00095-9. PMID: 37407134.
Yao JM, Otoukesh S, Kim H, Yang D, Mokhtari S, Samara Y, Blackmon A, Arslan S, Agrawal V, Pourhassan H, Amanam I, Ball B, Koller P, Salhotra A, Becker P, Curtin P, Artz A, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 Aug;29(8):515.e1-515.e7. doi: 10.1016/j.jtct.2023.05.008. Epub 2023 May 12. PMID: 37182736; PMCID: PMC10527340.
Aldoss I, Gu Z, Afkhami M, Mokhtari S, Pullarkat V. Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy. Leuk Lymphoma. 2023 Jun;64(6):1092-1101. doi: 10.1080/10428194.2023.2197538. Epub 2023 Apr 6. PMID: 37021793.
La Rosa C, Chiuppesi F, Park Y, Zhou Q, Yang D, Gendzekhadze K, Ly M, Li J, Kaltcheva T, Ortega Francisco S, Gutierrez MA, Ali H, Otoukesh S, Amanam I, Salhotra A, Pullarkat VA, Aldoss I, Rosenzweig M, Aribi AM, Stein AS, Marcucci G, Dadwal SS, Nakamura R, Forman SJ, Al Malki MM, Diamond DJ. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. Front Immunol. 2023 Mar 3;14:1114131. doi: 10.3389/fimmu.2023.1114131. PMID: 36936918; PMCID: PMC10020189.